Regulatory macrophages in solid organ xenotransplantation

Area of Science:

• Immunology
• Transplantation Biology
• Cellular Therapy

Background:

• Xenotransplantation, using pig organs, faces challenges due to immune rejection caused by species-specific glycans.
• Genetically modified pigs and human complement inhibitors reduce hyperacute rejection but inflammation and coagulation issues persist.
• Regulatory macrophages (Mregs) possess anti-inflammatory properties and secrete key cytokines like IL-10 and TGF-β.

Purpose of the Study:

• To explore the potential of regulatory macrophages (Mregs) as a therapeutic strategy to mitigate immune responses in pig-to-primate xenotransplantation.
• To investigate the mechanisms of Mreg generation, stability, and immunomodulatory functions for potential in vitro therapeutic applications.

Main Methods:

• Review of current strategies in xenotransplantation, including genetic modification of donor pigs.
• Discussion of the role of regulatory macrophages (Mregs) in immune suppression and tolerance induction.
• Highlighting the markers and induction methods for Mregs, such as dehydrogenase/reductase 9 expression.

Main Results:

• Genetically modified pigs reduce hyperacute rejection, but inflammation and coagulation dysregulation remain significant hurdles.
• Regulatory macrophages (Mregs) secrete IL-10 and TGF-β, promoting regulatory T cell development and suppressing immune responses.
• Mregs are typically induced from monocytes/macrophages using M-CSF and IFN-γ, expressing the marker dehydrogenase/reductase 9.

Conclusions:

• Understanding Mreg mechanisms is crucial for their therapeutic application in xenotransplantation.
• In vitro generated Mregs could reduce the need for anti-inflammatory and immunosuppressive drugs in preclinical and clinical settings.
• Mreg-based therapies offer a promising avenue to improve outcomes for pig organ transplantation.